	US 11,666,595 B2
	Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
Tamara Thelemann, Munich (DE); Frank Jaschinski, Puchheim (DE); and Richard Klar, Munich (DE)
Assigned to Secarna Pharmaceuticals GmbH & Co. KG, Marburg (DE)
Appl. No. 16/340,318
Filed by Secarna Pharmaceuticals GmbH & Co. KG, Marburg (DE)
PCT Filed Oct. 6, 2017, PCT No. PCT/EP2017/075511 § 371(c)(1), (2) Date Apr. 8, 2019, PCT Pub. No. WO2018/065589, PCT Pub. Date Apr. 12, 2018.
Claims priority of application No. 16002166 (EP), filed on Oct. 7, 2016.
Prior Publication US 2020/0009181 A1, Jan. 9, 2020
Int. Cl. A61K 31/7125 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/7125 (2013.01) [C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01)]

5 Claims

1. An oligonucleotide consisting of 17 nucleotides, wherein the nucleobase sequence of the oligonucleotide is that of SEQ ID NO:107, wherein said oligonucleotide is a gapmer comprising at least one LNA nucleotide within the stretch of 5 nucleotides at the 5′-end of said oligonucleotide, and at least one LNA nucleotide within the stretch of 5 nucleotides at the 3′-end of said oligonucleotide.